ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Causal Prediction of TP53 Variant Pathogenicity Using a Perturbation-Informed Protein Language Model.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Accurate prediction of variant functional impact is crucial for understanding human diseases, particularly for cancer-related genes such as TP53. Advances in high-throughput mutational assays have enhanced variant effect prediction (VEP), but missense classification remains challenging due to the limitations of broad, non-gene-specific models. Here we present CaVepP53, a TP53-specific predictor fine-tuned on perturbation-based experimental variants. The model not only classifies mutations but also quantifies their pathogenicity by calculating Euclidean distances between the wild-type and mutant embeddings and deriving confidence scores through logistic transformation. Benchmarking demonstrates that CaVepP53 significantly outperforms general-purpose models, such as AlphaMissense (AM) and PrimateAI-3D, achieving higher accuracy, precision, and F1-score in predicting pathogenic mutations. Competitive growth assay validation of 22 mutations further confirms CaVepP53's robustness, including 7 functional novel variants absent in the ClinVar database. Thus, by integrating protein language models with experimentally validated functional data, our approach enables accurate, interpretable VEP for TP53, overcoming limitations of predictors trained solely on evolutionary or clinical associations. We further extended this framework to five additional cancer-related genes (VHL, ATM, BRCA1, RAD51C, and BAP1), establishing a generalizable framework for gene-specific VEP with potential applications in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.